At Royalty Pharma, we believe that our ESG strategy, policies and practices will create sustainable long-term value for our company, employees, shareholders and other stakeholders.
Managing our business
Risk management, compliance and high ethical standards are foundational to our culture
Our strong corporate governance program, from board oversight to robust management practices, aligns the interests of our stakeholders and underpins our market-leading position.
The Chairman of our Board is our founder, Pablo Legorreta, who has also led the Company as CEO since its inception. 90% of our Board is independent, and 100% of our Board committees are comprised of independent directors.
Engaging our shareholders
We communicate with our investors regularly through investor meetings and conferences, management roadshows, press releases, conference calls and through our website.
We have established a dedicated, cross-functional ESG Committee, comprised of managers and team leads across several departments, that aims to formalize and strengthen our ESG efforts throughout the business.
Our policies and practices
Robust governance policies and practices
Royalty Pharma’s policies and practices adhere to high standards.
Ethics and compliance
We have clear codes of conduct for our talent and suppliers as well as comprehensive data privacy, cybersecurity, Whistleblower and Human Rights policies.
Our Environmental, Social and Governance (ESG) Report is aligned with Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) reporting standards.
Our commitment to the environment
Committed to implementing key sustainability practices across our operations
We continue to implement key sustainability practices across our operations and take steps to measure, manage and minimize our environmental impact where possible.
Reducing our operational footprint
We are focused on tracking our carbon footprint, mitigating our impact where we can and identifying ways to reduce our environmental impact.
Our partner network
We look for partners who value environmental sustainability. This is particularly important because we do not conduct biopharmaceutical research and development or manufacture or market biopharmaceutical products.